Jermendy György
Fővárosi Bajcsy-Zsilinszky Kórház III. Belgyógyászati Osztály Budapest Maglódi.
Orv Hetil. 2011 Nov 27;152(48):1931-40. doi: 10.1556/OH.2011.29238.
In the last couple of years, a new class of antidiabetic drugs became available for the clinical practice. Due to the intensive research, several new drugs reached the market. Among the incretinmimetics both the GLP-1 (glucagon like peptide-1)-receptor agonist exenatide and the GLP-1-analogue liraglutide can be used for treatment. As for incretin enhancers (dipeptidyl-peptidase-4 [DPP-4]-inhibitors), sitagliptin, vildagliptin and saxagliptin are available in Hungary, linagliptin will be introduced to the market in the near future. In clinical practice, any incretin-based new drugs can be used for treating patients with type 2 diabetes, preferably in combination with metformin. The clinical experiences with these new drugs are reviewed focusing on both the benefits and the potential side-effects of the particular compounds.
在过去几年中，一类新型抗糖尿病药物已可用于临床实践。由于深入研究，几种新药已投放市场。在肠促胰岛素类似物中，胰高血糖素样肽-1（GLP-1）受体激动剂艾塞那肽和GLP-1类似物利拉鲁肽均可用于治疗。至于肠促胰岛素增强剂（二肽基肽酶-4 [DPP-4]抑制剂），匈牙利有西他列汀、维格列汀和沙格列汀，利奈格列汀将在不久的将来投放市场。在临床实践中，任何基于肠促胰岛素的新药均可用于治疗2型糖尿病患者，最好与二甲双胍联合使用。本文将重点回顾这些新药的临床经验，包括特定化合物的益处和潜在副作用。
